Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the Efficacy and Safety of Single, Daily Oral Doses of SYN-010 Compared to Placebo in Adult Patients With Irritable Bowel Syndrome With Constipation (EASE-DO)

Next Previous
Trial Profile

Evaluation of the Efficacy and Safety of Single, Daily Oral Doses of SYN-010 Compared to Placebo in Adult Patients With Irritable Bowel Syndrome With Constipation (EASE-DO)

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 27 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lovastatin (Primary)
  • Indications Irritable bowel syndrome
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 01 Dec 2022 Results from NCT03763175 and NCT04557215; evaluating distinct gut microtypes linked to breath gas patterns in IBS-C and IBS-D subjects, published in the American Journal of Gastroenterology
    • 27 Oct 2021 Results of post-hoc analysis evaluating correlation between exhaled CH4 levels and heart rate and vagal tone, presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021
    • 23 May 2021 Results (n=53) assessing cytokine profile associated with change in exhaled methane over a 14-week time period ; serum and stool samples were collected at two different timepoints from subjects with IBS-C and IMO presented at the Digestive Disease Week 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top